Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk

Publication Date: November 1, 2019
Last Updated: March 14, 2022

NLA Recommendation on Use of Icosapent Ethyl for ASCVD Risk Reduction

For patients 45 years of age or older with clinical ASCVD, or 50 years of age or older with diabetes mellitus requiring medication and ≥1 additional risk factor,* with fasting TG 135-499 mg/dL on high-intensity or maximally tolerated statin, with or without ezetimibe, treatment with icosapent ethyl is recommended for ASCVD risk reduction.

(I, B-R)

* Additional risk factors include the following, based on the entry criteria in REDUCE-IT: age (men ≥55, women ≥65 years of age), cigarette smoker or stopped smoking within 3 months, hypertension (treated or untreated), HDL-C ≤40 mg/dL for men or ≤50 mg/dL for women, hs-CRP >3.0 mg/L, renal dysfunction with creatinine clearance >30 and <60 mL/min, retinopathy, micro- or macroalbuminuria, ankle-brachial index <0.9 without symptoms of intermittent claudicatio .

573

Overview

Title

Use of Icosapent Ethyl in Statin-treated Patients with Elevated Triglycerides and High or Very High ASCVD Risk

Authoring Organization

National Lipid Association